Evidence map›Paper›PMID 40978276›Full record

ArticleAmerican journal of stem cells2025

The effect of decitabine on human induced pluripotent stem cells (hiPSCs) derived CD34

Yanfeng Liu, Hongyan Zhang, Yanxin Li, Chuanli Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of stem cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yanfeng LiuDepartment of Hematology, Qilu Hospital of Shandong University Jinan 250102, Shandong, China.
Hongyan ZhangDepartment of Hematology, Qingdao Municipal Hospital Qingdao 266071, Shandong, China.
Yanxin LiKey Laboratory of Pediatric Hematology and Oncology Ministry of Health, Department of Hematology and Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine Shanghai 200127, China.
Chuanli ZhaoDepartment of Hematology, Qilu Hospital of Shandong University Jinan 250102, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpigenetic modifiers play an important role in regulating the fate of hematopoietic stem cells (HSCs). The chromatin-modifying agents (CMA) have previously been shown to expand HSCs from cord blood (CB) and bone marrow (BM) CD34

objectiveIt's unknown if decitabine could affect CD34

methodsWe utilized serum free, exon free and feeder free differentiation system to generate CD34

resultsThe proliferation and function of CD34

conclusionsThese results suggested that the effect of decitabine on CD34

Indexed as

CD34+ cellsdecitabineHuman induced pluripotent stem cells (hiPSCs)megakaryocytes

Identifiers

PMID40978276
PMCPMC12444434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.